Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Obstructive Sleep Apnea, Fetal Growth Restriction, Pregnancy Related
Interventions: S9 VPAP Adapt; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: St Louis, Missouri • Rochester, New York

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 1 Month
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 13 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Urea Cycle Disorder
Interventions: Not listed
Lead sponsor: Amgen; Industry
Eligibility: Not listed
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Blue Bell, Pennsylvania

Conditions: Labour Onset and Length Abnormalities, Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions: Dilapan-S; Device
Lead sponsor: Medicem International CR s.r.o.; Industry
Eligibility: Female only
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New York, New York • Galveston, Texas

Conditions: Abdominal Surgery, Thoracic Surgery
Interventions: Morphine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Minute to 70 Days
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Interventions: Stryker's PEEK Customized Implant; Device
Lead sponsor: Stryker Craniomaxillofacial; Industry
Eligibility: 42 Months and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Louisville, Kentucky • New Brunswick, New Jersey • New York, New York + 2 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 292
States / cities: Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more

Conditions: Phenylketonuria (PKU)
Interventions: MZE782, Placebo; Drug · Other
Lead sponsor: Maze Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Oakland, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Sickle Cell Disease
Interventions: Digital app and information system; Other
Lead sponsor: Makerere University; Other
Eligibility: Up to 5 Years
Enrollment: 24,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia B
Interventions: rFIXFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more

Conditions: GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2, Tay-Sachs Disease, AB Variant Gangliosidosis GM2, Sandhoff Disease
Interventions: Not listed
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 0 Months and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Diet and water adjustment; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurofibromatosis Type 1
Interventions: Lovastatin ™, placebo; Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 15 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Sickle Cell Anemia Crisis
Interventions: Acetaminophen, Normal saline; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 4 Years to 16 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Newark, New York

Conditions: Sickle Red Blood Cell, Fetal Hemoglobin, Oxidative Stress
Interventions: Broccosprouts® (Brassica Protection Products LLC) homogenate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myotonic Dystrophy Type 1 (DM1)
Interventions: DYNE-101, Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 8
States / cities: Stanford, California • Gainesville, Florida • Indianapolis, Indiana + 5 more

Conditions: HIV, AIDS, Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder
Interventions: Opt-in or Opt-out testing, Focus Group; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions: Deferoxamine Product, Placebo; Drug · Other
Lead sponsor: TauTona Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Angelman Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 5 more

Conditions: Anemia, Sickle Cell
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystinosis, Nephropathic Cystinosis
Interventions: Cysteamine bitartrate; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cystic Fibrosis
Interventions: Exercise Intervention; Behavioral
Lead sponsor: Wuerzburg University Hospital; Other
Eligibility: 12 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Search by objective public record fields.

Sleep Apnea and Fetal Growth Restriction

Comparison of NIRS and Serum Lactate to Predict Poor Post-operative Outcomes

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)

Dilapan-S/Dilasoft E-Registry in Induction of Labor

Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit

Pancreas Registry and High Risk Registry

Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

A Study of MZE782 in Adults With PKU

Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

Effect of Broccoli Sprouts Homogenate on SS RBC

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Expansion to Interdisciplinary HIV Prevention in Women

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

Angelman Syndrome Natural History Study

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

Effects of a Partially Supervised Conditioning Program in CF